STADA consolidates its growth with an increase in sales in the first half of 2023. This was the best result ever for the company, which posted a record annual profit of €1 billion, driven mainly by the Consumer Healthcare and Speciality division.
The best half-year results in the company's history were accompanied by growth in STADA's three strategic business segments, as the company announced in its press release: Consumer Health, Generics and Speciality. Stada's sales have increased in the first six months to 2.1 billion euros and EBITDA has increased by 30%. The company is satisfied that in the last five years it has more than doubled its profit.
Mar Fabregas, Managing Director of Stada in Spain explained the role of Spain in the company's growth: "As one of STADA's top 10 markets by sales, Spain made an important contribution to the group's excellent performance in the first half of this year."
The Consumer Health division, which has experienced the strongest growth and has driven this increase in profits, has registered several launches as well as line extensions and achieved sales of 870 million euros in the first six months of the year, representing 42% of the group's global turnover.
Peter Goldschmidt, CEO of STADA, has assessed these results very positively and revealed the group's outlook for the end of the year: "STADA's purpose, values and strategy are the basis for our continued double-digit growth in sales and profits. With this momentum, we are well on track to exceed EUR 4 billion in sales and EUR 1 billion in EBITDA this year".